

03-59000-18

Original Effective Date: 03/15/13

Reviewed: 01/26/23

Revised: 08/21/23

Subject: Noninvasive Prenatal Screening for Fetal Aneuploidies, Twin Zygosity, and Microdeletions Using Cell-Free Fetal DNA

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

DESCRIPTION:

National guidelines recommend that all pregnant individuals be offered screening for fetal chromosomal abnormalities, most of which are aneuploidies, an abnormal number of chromosomes. Trisomy syndromes are aneuploidies involving 3 copies of 1 chromosome. Trisomies 21, 18, and 13 are the most common forms of fetal aneuploidy that survive to birth. There are numerous limitations to standard screening for these disorders using maternal serum and fetal ultrasound. Noninvasive prenatal screening (NIPS) analyzing cell-free fetal DNA in maternal serum is a potential complement or alternative to conventional serum screening. NIPS using cell-free fetal DNA has also been proposed to screen for microdeletions. Prenatal testing for twin zygosity using cell-free fetal DNA has been proposed to inform decisions about early surveillance for twin-twin transfusion syndrome and other monochorionic twin-related abnormalities.

The technology for noninvasive, sequencing-based testing of maternal serum for fetal trisomy syndromes involves detection of cell-free fetal DNA fragments present in the plasma of pregnant individuals. As early as 8 to 10 weeks of gestation, these fetal DNA fragments comprise 6% to 10% or more of the total cell-free fetal DNA in a maternal plasma sample. The tests are unable to provide a result if the fetal fraction is too low (ie, <4%). Fetal fraction can be affected by maternal and fetal characteristics.

A newer approach to cell free DNA testing called the Vanadis NIPT does not involve polymerase chain reaction (PCR) amplification or sequencing. The procedure consists of digestion of cell-free DNA (cfDNA) using a restriction enzyme. The digested cfDNA is then hybridized and ligated to chromosome specific

DNA probes forming a circular DNA. All non-circular DNA is removed by exonuclease treatment. Finally, the circular DNA containing the cfDNA is amplified with rolling circle amplification to form rolling circle products that are labeled with chromosome-specific fluorescently labeled DNA probes. The fluorescently labeled rolling circle products are imaged and counted with an automated microscopy scanner. The microscope takes multiple images from each well with different spectral filters, i.e. each wavelength range presents a specific chromosome. With image analysis algorithms, the fluorescently labeled rolling circle products are counted for each sample. The ratio between the number of chromosome-specific rolling circle products is then transferred to risk calculation software to calculate the likelihood of a trisomy. Currently, Vanadis NIPT provides results for trisomy 21, trisomy 18 and trisomy 13, and fetal sex determination.

Single-gene disorders (also known as monogenic disorders) are caused by a variation in a single gene. Individually, single-gene disorders are rare, but collectively are present in approximately 1% of births. The Vistara Single-Gene Disorder Test panel screens for 25 conditions that result from variants across 30 genes. These include Noonan syndrome and other Noonan spectrum disorders, skeletal disorders (e.g., Osteogenesis Imperfecta, achondroplasia), craniosynostosis syndromes, Cornelia de Lange syndrome, Alagille syndrome, tuberous sclerosis, epileptic encephalopathy, SYNGAP1-related intellectual disability, CHARGE syndrome, Sotos syndrome, and Rett syndrome. The clinical presentation and severity of these disorders can vary widely. Some, but not all, can be detected by prenatal ultrasound examination.

POSITION STATEMENT:

NOTE: Coverage for genetic testing, screening, and counseling are applicable only under those contracts that include benefits for genetic testing, preventive health services, screening services, and medical counseling.

Nucleic acid sequencing-based testing of maternal plasma to screen for trisomy 21, 18, 13 **meets the definition of medical necessity** in members with singleton pregnancies.

Nucleic acid sequencing-based testing of maternal plasma for trisomy 13 and/or 18, other than in the situation specified above, is considered **experimental or investigational**. There is insufficient clinical evidence to permit conclusions on net health outcomes.

Nucleic acid sequencing-based testing of maternal plasma for trisomy 21 is considered **experimental or investigational** in members with twin or multiple pregnancies. The evidence is insufficient to determine the effects of the technology on health outcomes.

Nucleic acid sequencing-based testing of maternal plasma is considered **experimental or investigational** for the following indications:

- fetal sex chromosome aneuploidies
- microdeletions
- twin zygosity.

The evidence is insufficient to determine the effects of the technology on health outcomes.

Vanadis® NIPT of maternal plasma to screen for trisomy 21, 18 and 13 is considered **experimental or investigational** in all situations. The evidence is insufficient to determine the effects of the technology on health outcomes.

Vistara™ NIPT of maternal plasma to screen for single-gene disorders is considered **experimental or investigational** in all situations. The evidence is insufficient to determine the effects of the technology on health outcomes.

BILLING/CODING INFORMATION:

CPT Coding:

81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood (Investigational)
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy (Harmony™ Prenatal Test)
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood (Investigational)

CPT Code 88271 and unlisted codes 81599 and 81479 may also be used to report nucleic acid sequencing–based tests.

ICD-10 Diagnosis Codes That Support Medical Necessity:

O09.511	Supervision of elderly primigravida, first trimester
O09.512	Supervision of elderly primigravida, second trimester
O09.521	Supervision of elderly multigravida, first trimester
O09.522	Supervision of elderly multigravida, second trimester
Z31.430 – Z31.438	Encounter for genetic testing of female for procreative management
Z34.00 –Z34.93	Encounter for supervision of normal pregnancy
Z36.0-Z36.9	Encounter for antenatal screening of mother

REIMBURSEMENT INFORMATION:

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#)

DEFINITIONS:

No guideline specific definitions apply.

RELATED GUIDELINES:

[Genetic Testing, 05-82000-28](#)

OTHER:

Other names used to describe nucleic acid sequencing-based testing of maternal plasma:

Note: The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

- Harmony™ (T21, T18, T13)
- InformaSeqSM (T21, T18, T13 with optional testing for select sex chromosome abnormalities)
- MaterniT21™ PLUS (core test: T21, T18, T13, and fetal sex aneuploidies; enhanced sequencing series includes T16, T22, and microdeletions)
- Panorama™ (T21, T18, T13 and select sex chromosome abnormalities; extended panel includes microdeletions)
- Prequel™ Prenatal Screen (T21, T18, T13)
- QNatal™ (T21, T18, T13)
- Verifi® (T21, T18, T13)
- Vanadis® NIPT Solution (T21, T18, T13)
- Veracity Prenatal (T21, T18, T13, sex chromosome aneuploidies, and microdeletions)
- VisibiliT (T21 and T18).

REFERENCES:

1. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Advisory: Cell-free DNA to Screen for Single-Gene Disorders; accessed at acog.org.
2. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin #226, Screening for Fetal Chromosomal Abnormalities; accessed at smfm.org.
3. Bai T, Liu S, et al. Performance of noninvasive prenatal screening in twin pregnancies: a retrospective study of 5469 twin pregnancies. *J Matern Fetal Neonatal Med.* 2021 Apr 1;1-9. PMID: 33792471.

4. Blue Cross Blue Shield Association Evidence Positioning System®. 4.01.21 Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, and Twin Zygosity Using Cell-Free Fetal DNA, 09/22.
5. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Noninvasive maternal plasma sequencing-based screening for fetal aneuploidies other than trisomy 21. TEC Assessments 2014; Volume 29, Tab 7.
6. Blue Cross Blue Shield Association (BCBSA), Technology Evaluation Center (TEC). Sequencing-Based Tests to Determine Fetal Down Syndrome (Trisomy 21) from Maternal Plasma DNA, Volume 27, No. 10 April 2013.
7. Chen M, Jiang F, et al. Validation of fetal DNA fraction estimation and its application in noninvasive prenatal testing for aneuploidy detection in multiple pregnancies. *Prenat Diagn.* 2019 Dec;39(13):1273-1282. PMID: 31671222.
8. Chibuk J, Rafalko J, et al. Cell-free DNA screening in twin pregnancies: A more accurate and reliable screening tool. *Prenat Diagn.* 2020 Sep;40(10):1321-1329.
9. Dar P, Jacobsson B, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. *Am J Obstet Gynecol.* 2022 Jul;227(1):79.e1-79.e11.
10. Dyr B, Boomer T, et al. A new era in aneuploidy screening: cfDNA testing in 30,000 multifetal gestations: Experience at one clinical laboratory. *PLoS ONE.* 2019; 14(8): e0220979. PMID: 31393959.
11. Ericsson O, Ahola T, et al. Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma. *Prenat Diagn.* 2019;39(11):1011-1015. PMID: 31429096.
12. Gil MM, Galeva S, et al. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. *Ultrasound Obstet Gynecol.* Jun 2019; 53(6): 734-742.
13. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. *Ultrasound Obstet Gynecol.* 2013 Jul;42(1):34-40.
14. Gregg AR, Gross SJ, Best RG et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. *Genet Med* 2013; 15(5):395-8.
15. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med.* Oct 2016;18(10):1056-1065.
16. Judah H, Gil MM, et al. Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. *Ultrasound Obstet Gynecol.* 2021 Aug;58(2):178-189. PMID: 33838069.
17. Kypri E, Ioannides M, et al. Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test. *Mol Cytogenet.* 2019; 12: 34. PMID: 31338126.
18. Mohan P, Lemoine J, et al. Clinical experience with non-invasive prenatal screening for single-gene disorders. *Ultrasound Obstet Gynecol.* Jan 2022; 59(1):33-39.
19. Mortazavipour MM, Mahdian R, et al. The current applications of cell-free fetal DNA in prenatal diagnosis of single-gene diseases: A review. *Int J Reprod Biomed.* 2022 Sep 6;20(8):613-626.
20. Motevasselian M, Saleh Gargari S, et al. Non-invasive prenatal test to screen common trisomies in twin pregnancies. *Mol Cytogenet.* 2020; 13: 5. PMID: 32042312.
21. National Society of Genetic Counselors (NSGC), Noninvasive prenatal testing/ noninvasive prenatal diagnosis (NIPT/NIPD), accessed at nsgc.org.

22. Norwitz ER, McNeill G, et al. Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy. *J Clin Med*. 2019 Jun 28;8(7):937.
23. Palomaki GE, Messerlian GM, Halliday JV. Prenatal screening for common aneuploidies using cell-free DNA. In *UpToDate*, Wilkins-Haug L, Barss VA (Eds), UpToDate, Waltham, MA; accessed at uptodate.com.
24. Porreco RP, Garite TJ, Maurel K, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. *Am J Obstet Gynecol*. Mar 19 2014.
25. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. *Am J Obstet Gynecol*. Dec 2015;213(6):753-754.
26. Tan Y, Gao Y, et al. Noninvasive prenatal testing (NIPT) in twin pregnancies with treatment of assisted reproductive techniques (ART) in a single center. *Prenat Diagn*. 2016 Jul;36(7):672-9. PMID: 27150972.
27. Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. *BMJ Open*. 2016;6(1):e010002.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 01/26/23.

GUIDELINE UPDATE INFORMATION:

03/15/13	New Medical Coverage Guideline.
07/01/13	Quarterly HCPCS updates. Added code 0005M. Revised Program Exception section.
10/15/13	Revision; position statements and guideline title updated; formatting changes.
01/01/14	Annual HCPCS update. Added code 81507; deleted code 0005M.
03/15/14	Annual review; position statements maintained and references updated.
01/01/15	Annual HCPCS/CPT update. Added code 81420.
04/15/15	Annual review; position statements and references updated; formatting changes.
09/15/15	Revision; update position statement and references; formatting changes.
11/15/15	Revision; coding section updated.
12/15/16	Revision; title, description, position statements, and references updated; formatting changes.
01/01/17	Annual CPT/HCPCS update. Added 81422.
07/01/18	Quarterly CPT/HCPCS update. Added code 0060U.
08/01/18	Revision; ICD10 codes added.
10/15/18	Revision; coverage statement, description, coding, and references updated.
01/01/20	Annual CPT/HCPCS coding update. Deleted code 0009M.
04/01/20	Quarterly CPT/HCPCS update. Added code 0168U.
11/15/20	Review; Position statements and references updated.
10/01/21	Quarterly CPT/HCPCS update. Deleted code 0168U.
11/15/21	Review: Position statements maintained and references updated.

02/15/23	Review: Position statements, description, coding, and references updated.
08/21/23	Update to Program Exceptions section.